(Q44225342)

English

Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 December 2017

Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism (English)

1 reference

Europe PubMed Central

1 December 2017

0 references

author name string

Junji Ichikawa

1

1 reference

Europe PubMed Central

1 December 2017

Zhu Li

2

1 reference

Europe PubMed Central

1 December 2017

Jin Dai

3

1 reference

Europe PubMed Central

1 December 2017

Herbert Y Meltzer

4

1 reference

Europe PubMed Central

1 December 2017

language of work or name

0 references

publication date

1 November 2002

1 reference

Europe PubMed Central

1 December 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

1 December 2017

956

1 reference

Europe PubMed Central

1 December 2017

2

1 reference

Europe PubMed Central

1 December 2017

349-357

1 reference

Europe PubMed Central

1 December 2017

Prazosin modulates the changes in firing pattern and transmitter release induced by raclopride in the mesolimbic, but not in the nigrostriatal dopaminergic system.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

(R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

Effects of atypical antipsychotic agents on social behavior in rodents

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

Agonist-stimulated GTPγ[35S] binding to 5-HT1A receptors in human post-mortem brain

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

Activation of tuberoinfundibular dopamine neurons following the acute administration of atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

Serotonergic regulation of acetylcholine release in rat frontal cortex

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

The effect of chronic atypical antipsychotic drugs and haloperidol on amphetamine-induced dopamine release in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

DOI, a 5-HT2A/2C receptor agonist, attenuates clozapine-induced cortical dopamine release

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

An assessment of iloperidone for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

Iloperidone binding to human and rat dopamine and 5-HT receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

Enhancement of cortical and hippocampal cholinergic neurotransmission through 5-HT1A receptor-mediated pathways by BAY x 3702 in freely moving rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

Effects of atypical antipsychotic drugs on dopamine output in the shell and core of the nucleus accumbens: role of 5-HT(2A) and alpha(1)-adrenoceptor antagonism

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

The role of serotonin in antipsychotic drug action

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

Melperone in the treatment of neuroleptic-resistant schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

Efficacy of antipsychotic agents at human 5-HT(1A) receptors determined by [3H]WAY100,635 binding affinity ratios: relationship to efficacy for G-protein activation

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

Seroquel: biochemical profile of a potential atypical antipsychotic.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

Antipsychotic drug doses and neuroleptic/dopamine receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

MKC-242, a novel 5-HT1A receptor agonist, facilitates cortical acetylcholine release by a mechanism different from that of 8-OH-DPAT in awake rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and alpha 1-adrenoceptor antagonism [corrected]

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

The alpha 2-adrenoceptor antagonist, (+)-efaroxan, enhances acetylcholine release in the rat cortex in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

Seroquel (ICI 204 636), a putative "atypical" antipsychotic, in schizophrenia with positive symptomatology: results of an open clinical trial and changes of neuroendocrinological and EEG parameters

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

Muscarinic m4 receptor activation by some atypical antipsychotic drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

Clozapine is a potent and selective muscarinic M4 receptor agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

Melperone and clozapine: neuroendocrine effects of atypical neuroleptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903570-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0006-8993(02)03570-9

1 reference

Europe PubMed Central

1 December 2017

1 reference

Europe PubMed Central

1 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44225342&oldid=2108725026"